Table 3 |
||||||
|
tmax(h) |
Bioavailability (%) |
T1/2 (h) |
Vd (L) |
Interaction with food |
Hepatic elimination (%) |
|
|
|
||||||
|
Candesartan |
3.0-5.0 |
42 |
9-13 |
0.13 (L/kg) |
No |
67 |
|
|
||||||
|
Eprosartan |
2.0-6.0 |
13 |
5-7 |
308 |
No |
90 |
|
|
||||||
|
Irbesartan |
1.0-2.0 |
60-80 |
12-20 |
53-93 |
No |
80 |
|
|
||||||
|
Losartan |
1.0 (3.0-4.0)1 |
33 |
2 (4-6)1 |
34 (12)1 |
No |
60 |
|
|
||||||
|
Olmesartan |
1.4-2.8 |
262 |
11.8-14.7 |
15-20 |
No |
51-663 |
|
|
||||||
|
Telmisartan |
1 |
43 |
24 |
500 |
No |
> 984 |
|
|
||||||
|
Valsartan |
2 |
23 |
7 |
17 |
No |
83 |
|
|
||||||
|
Azilsartan |
1.5-3.0 |
60 |
11 |
16 |
No |
55 |
|
|
||||||
|
Abbreviations: ARB = angiotensin II receptor blocker; t1/2 = terminal elimination half-life; tmax = time to maximum plasma concentration; Vd = volume of distribution 1 Values in parentheses are for the active metabolite of losartan 2 For olmesartan medoxomil 3 Based on urinary recovery rate for intravenous olmesartan 4 Faecal recovery for telmisartan |
||||||
|
Mallat Cardiovascular Diabetology 2012 11:32 doi:10.1186/1475-2840-11-32 |
||||||
